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Abstract
Background: Policies concerning the prevention of transfusion transmitted malaria (TTM) are the responsibility of blood
transfusion services and malaria control programmes. To prevent spreading drug resistance due to over-use of malaria
drugs, recent malaria treatment guidelines recommend prompt parasitological confirmation before treatment is started. In
contrast, blood safety policies from the World Health Organisation (WHO) recommend presumptive malaria treatment for
recipients of blood in endemic countries but evidence supporting this approach is lacking. Our study documented how
these conflicting policies relating to malaria transmission through blood transfusion impact on clinical practice in a teaching
hospital in West Africa.
Methods/Principal Findings: We randomly selected and reviewed case notes of 151 patients within 24 hours of their
receiving a blood transfusion. Transfusion practices including the confirmation of diagnosis and anti-malarial treatment
given were compared across three departments; Obstetrics and Gynaecology (O&G), Paediatrics and Medicine. Overall, 66
(44%) of patients received malaria treatment within 24 hrs of their blood transfusion; of which only 2 (3%) received anti-
malarials based on a laboratory confirmation of malaria. Paediatric patients (87%) received the most anti-malarials and only
7% and 24% of recipients in medicine and O&G respectively received anti malarials. In 51 patients (78%), the anti-malarials
were prescribed at the same time as the blood transfusion and anti-malarials prescriptions exceeded the number of patients
with a presumptive diagnosis of malaria.
Conclusions: It is common practice in paediatrics to prescribe anti-malarials routinely with blood transfusions. This
contravenes the malaria treatment guidelines of laboratory confirmation before treatment but is in accordance with the
less-well evidenced blood safety guidelines. There is an urgent need for more evidence about the clinical impact of
transfusion transmitted malaria to enable malaria and blood transfusion programmes to harmonize their policies and give
clear guidance to clinicians who prescribe blood transfusions in malaria-endemic areas
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Introduction
Malaria is one of the most important parasitic diseases in the
world. In 2009, there were approximately 225 million malaria cases
in the world with 781,000 deaths [1]. Current measures to reduce
the burden of malaria include insecticide- treated mosquito nets,
intermittent preventive treatment, indoor residual spraying and
malaria vaccines. An area of malaria control which has been
neglected in endemic countries is malaria transmission through
blood transfusion. Although blood transfusion has been recognised
as one of the transmission routes for malaria since 1911 [2] the
prevalence of transfusion transmitted malaria (TTM) in sub-Saharan
Africa remains unknown. In endemic countries a substantial
proportion of the population have asymptomatic parasitaemia. This
makes it difficult to be sure whether malaria occurring after blood
transfusion was acquired from the transfusion or not.
There are no evidence-based international guidelines for the
prevention of TTM in sub-Saharan Africa and there is lack of
harmonisation between policies produced by blood safety
programmes and policies by malaria programmes. The World
Health Organisation (WHO) recommends that donated blood
should be tested for malaria ‘‘where appropriate and possible’’, [3]
but there is currently no method for screening blood for low-level
parasitaemia that is sensitive, practical and affordable for use by
transfusion services in endemic countries [4]. Microscopy is the
most commonly used test but it is time-consuming and
insufficiently sensitive [5]. Other transfusion guidelines suggest
that transfusion recipients should be given prophylaxis with anti-
malarials [6]. In the past, administration of anti-malarials such as
chloroquine to recipients of blood transfusions was a widespread
practice. Resistance to chloroquine means that it has largely been
replaced by the more expensive artemisinin-based therapies and
this has increased the cost of treating all transfusion recipients with
anti-malarials by 5–7 fold making this practice unaffordable on a
wide scale [7,8]. In contrast to blood safety policies, malaria
policies recommend that malaria treatment should only be
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prescribed on the basis of laboratory confirmation of infection [9]
in order to reduce the development of drug resistance.
There are therapeutic dilemmas related to the use of anti-
malarials and antibiotics in association with blood transfusions
which are particularly apparent in paediatric practice. Anti-
malarials are given presumptively on the basis that most febrile
children have underlying malaria and that they are at high risk of
transfusion-transmitted malaria. In the case of antibiotics the
presumptions are that non-malaria infections are common in
febrile children and that post-transfusion fever is frequently due to
bacterial infections.
There is very little information in the literature about how
African countries have incorporated WHO’s recommendations
concerning transfusion-transmitted malaria into their national
policies and how these policies have been translated into practice.
The Democratic Republic of Congo, Comoros and Malawi are
carrying out some screening of donated blood for malaria using
microscopy [10]. Other countries such as Nigeria and Rwanda do
not have any policy for reducing TTM and a survey of seven sub-
Saharan Francophone African countries found that none of them
were systematically screening blood donors for malaria [11]. In the
absence of clear national policies clinicians may rely on
international recommendations which may not be applicable in
their setting or they use individualised practices that are not based
on evidence.
Ghana’s malaria policy recommends laboratory confirmation of
malaria before starting treatment in all situations except for
children under 5 years and for suspected severe malaria if
laboratory confirmation is not immediately possible. The first line
treatment for uncomplicated malaria which is the only type likely
to be present in clinically well blood donors is oral artesunate-
amodiaquine [12]. As in many other countries in sub-Saharan
Africa, the blood transfusion policy in Ghana makes no mention of
screening donated blood for malaria or of treating recipients
prophylactically. The aim of our study was to document how these
conflicting or absent policies relating to malaria transmission and
blood transfusion impact on clinical practice in a teaching hospital
in West Africa. Analysis of discrepancies between policies and
practice would enable us to identify priorities for better
harmonisation of policies and to identify gaps in the evidence
regarding TTM.
Methods
Approval was given for this study by 2 ethics committees: the
Liverpool School of Tropical Medicine, Research Ethics Com-
mittee in Liverpool, UK and the Committee on Human Research
Publication and Ethics (CHRPE) of the School of Medical
Sciences, Kwame Nkrumah University of Science and Technology
in Kumasi, Ghana.
This study was conducted at the Komfo Anokye Teaching
Hospital (KATH) in the Ashanti region of Ghana between
October and November 2009. KATH is the second largest
hospital in Ghana and the referral centre for the middle and
northern parts of the country. It has a 1000 bed capacity and
carries out about 14,500 whole blood transfusions per year. There
are no hospital based guidelines for the clinical use of blood or any
written policies or protocols concerning transfusion transmitted
malaria. The blood bank has transfusion monitoring forms which
are given to ward staff when the blood is issued and are used for
reporting any transfusion reactions.
Transfusion recipients from the departments of Obstetrics and
Gynaecology, Paediatrics and Medicine were included in the
study. These departments were selected because they use the
majority (66%) of blood in the hospital. All patients in these
departments who had received a transfusion within the previous
24 hours were eligible for the study. Exclusion criteria were
untraceable case notes, transfer to a department not included in
this study or more than one transfusion within the 24 hour time
period. Each day the blood bank staff provided AOO with the
names of two blood transfusion recipients in each of the three
departments. The recipients were selected randomly from the list
of patients who had received blood in the preceding 24 hours. On
six occasions during the two month study a department had less
than two transfusion recipients in 24 hours and so the name of a
replacement participant from another department was provided
by the blood bank staff. On one occasion the case notes of a
patient from obstetrics could not be traced and as no other
obstetric patient was eligible, a replacement was recruited from
paediatrics.
At recruitment, a data collection form was used to extract
information from the clinical notes of the transfusion recipients.
The form was adapted from the KATH transfusion monitoring
form, which is based on the national guidelines for the clinical use
of blood in Ghana. The form was expanded to include information
about the patient’s diagnoses, laboratory tests (such as malaria
microscopy, pre-transfusion haemoglobin) and treatment type
(such as anti-malarials, antibiotics, diuretics). Information was also
collected on monitoring of vital signs, duration of transfusion and
documentation of adverse events of transfusion.
Predictive Analytics Software (PASWH) statistics 18 package
(SPSS Inc, USA) was used to calculate frequency statistics
including measures of central tendency and dispersion and the
results were compared between the three departments. The
practices relating to the prevention and treatment of malaria
associated with transfusion were compared with known policies.
Results
151 transfusion recipients were recruited into the study from
medicine (41, 27.2%), obstetrics (51, 33.7%) and paediatrics (59,
39.1%). The majority of patients (64.9%) were female, because of
the inclusion of the obstetric department, and the median age of all
patients was 22.0 years (IQR: 4.0–36.0) (Table 1). 25 patients
(16.6%) had received a blood transfusion during a previous
admission and the highest rates of previous transfusions were in
the department of medicine (45.5%). 66% of transfusion recipients
from medicine, 65% from obstetrics and 15% from paediatrics
had received a transfusion during the current admission prior to
enrolment in the study. The mean pre-transfusion haemoglobin in
all the transfusion recipients in the study was 4.5 g/dl (SD61.2)
(Table 1). All patients received either whole blood or packed red
cells. The mean duration of transfusion for all study participants
was 2.6 hours and was longest for paediatric transfusions
(3.3 hours). Ninety four percent of all transfusions were completed
(Table 1). There were 10 deaths (7%) among recipients within
24 hours of transfusion but none of these were attributed to the
blood transfusions.
Sixty six (44%) patients received malaria treatment within
24 hours of their blood transfusion. There was marked variation in
the use of anti-malarial drugs between departments with 51 (87%)
children receiving malaria treatment compared to 12 (24%)
obstetric patients and 3 (7%) adult medical patients (Table 2). In
51 of these patients (78%) the anti-malarials were prescribed at the
same time as the blood transfusion. 84% (43/51) of those who
received anti-malarials with the transfusion were children and only
one had parasitaemia confirmed by microscopy. Eight patients
had received anti-malarials at least 24 hours prior to transfusion
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and in 3 patients the timing of the anti-malarials was unknown.
The temperatures charts for all transfusion recipients revealed that
34 (23%) developed fever in the 24 hours following transfusion.
Post-transfusion fever was a particular problem in obstetric (24%)
and paediatric (32%) transfusion recipients. Four transfusion
recipients with post-transfusion fever received anti-malarials
because it was thought that malaria was the cause of the fever.
There was however only one malaria case confirmed on a blood
film (Table 2). Information from patients’ case notes indicated that
clinically-suspected malaria was a reason for hospitalisation in 50
(30%) of the transfusion recipients; 70% of these were children.
Within the department of paediatrics, a clinical diagnosis of
malaria was made more frequently in younger children (Table 3).
Overall 20 transfusion recipients (13%), 10/59 (17%) children, 3/
51 (6%) obstetric patients and 7/41 (17%) medical patients,
received malaria treatment with their transfusion or within
24 hours post-transfusion despite having no underlying clinical
diagnosis of malaria, and 64 (42%) transfusion recipients were
treated for malaria without any laboratory confirmation of
parasitaemia. Quinine (40% of all anti-malarial prescriptions)
and artesunate-amodiaquine (33%) were the most commonly
prescribed anti-malarial drugs and these were used exclusively by
the department of paediatrics. Quinine, which is recommended for
severe malaria, was used more frequently in younger children
(Table 3). The only anti-malarials prescribed in the departments of
medicine and obstetrics and which formed 27% of all prescribed
anti-malarials was artemeter-lumefantrine. No chloroquine or
sulphadoxine-pyrimethamine was prescribed for any transfusion
recipient.
Overall 118 transfusion recipients (78%) received antibiotics,
with the highest usage in obstetrics (96%) (Table 2). 81% of
antibiotics were prescribed prior to the blood transfusion. 40% of
all transfusion recipients, predominantly paediatric patients (88%),
had furosemide prescribed at the same time as the blood
transfusion (Table 2). The reason for prescribing a diuretic was
only documented in the notes of two patients both of whom had
heart failure. In 96% of patients there was no indication of why
furosemide was given.
Table 1. Characteristics and practices among transfusion recipients within three departments in a Ghanaian Teaching Hospital.
All (N=151) Medicine (N=41)
Departments Obstetrics
(N=51) Paediatrics (N=59)
Median age (IQR)yrs 22.0 (4.0–36-0) 41.0 (29.5–56.0) 28.0 (22.0–38.0) 3.0 (1.0–6-0)
Completed transfusion (%) 142 (94.0) 36 (87.8) 51 (100) 55 (93.2)
.1 transfusion received (%) 82 (54.3) 27 (65.9) 33 (64.7) 9 (15.3)
Mean pre-transfusion haemoglobin 6SD (g/dl) 4.561.2 4.461.7 4.761.2 4.360.9
Mean duration of transfusion 6SD (hrs) 2.661.2 2.261.1 2.060.8 3.361.0
Documentation of transfusion reactions 13 (8.6) 4 (9.8) 5 (9.8) 4 (6.7)
Death within 24 hrs of transfusion (% ) 10 (6.6) 6 (14.6) 2 (3.9) 2 (3.3)
O&G represents Obstetrics and Gynaecology; IQR represents interquartile range; SD represents standard deviation.
doi:10.1371/journal.pone.0034201.t001
Table 2. Practices related to transfusion transmitted malaria in three hospital departments.
All (N=151) Medicine(N=41) O&G(N=51) Paediatrics(N=59)
n (%) n (%) n (%) n (%)
Clinical diagnosis of malaria in admission (%) 50 (30) 0 (0) 9 (18) 41* (70)
Anti-malarial use (%) 66 (44) 3 (7) 12 (24) 51 (87)
Type of anti-malarial given
Quinine 26 (40) 0 (0) 0 (0) 26 (51)
Artemether-Lumefantrine 18 (27) 3 (100) 12 (100) 3 (6)
Artesunate-Amodiaquine 22 (33) 0 (0) 0 (0) 22 (43)
Time of prescribing anti-malarial
With transfusion 51 (77) 1 (33) 7 (59) 43 (84)*
At least 24 hours before transfusion 8 (12) 1 (33) 1 (8) 6 (12)
Within 24 hours post- transfusion 4 (6) 0 (0) 3 (25)* 1 (2)
Unknown 3 (5) 1 (33) 1 (8) 1 (2)
Other drugs
Furosemide (%) 60 (40) 2 (5) 6 (12) 52 (88)
Antibiotics use (%) 118 (78) 25 (61) 49 (96) 44 (75)
Post transfusion fever (%) 34 (23) 3 (7) 12 (24) 19 (32)
*confirmed by positive malaria microscopy in one case.
doi:10.1371/journal.pone.0034201.t002
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Discussion
In Ghana, as in many other malaria endemic countries in sub-
Saharan Africa, blood for transfusion is not screened for malaria
and there are no clear policies about whether or not anti-
malarials should be prescribed presumptively with blood
transfusions. 44% of all transfusion recipients in our study
received malaria treatment with their blood transfusion (77%) or
in the 24 hours following the transfusion (6%) but only two (3%)
had parasitaemia confirmed on microscopy. This practice of
routine prescription of anti-malarials with blood transfusions
without laboratory confirmation of infection occurred predom-
inantly in paediatrics. Many of the children had a clinical
diagnosis of malaria so it is possible that the anti-malarials were
prescribed presumptively for their suspected infection. However,
in children, 98% of malaria drugs for which the timing was
known, were prescribed simultaneously with the blood transfu-
sion and the number of children prescribed anti-malarials
exceeded the number with suspected malaria. This indicates that
in paediatric practice anti-malarial drugs are prescribed routinely
with blood transfusions.
Prescribing malaria treatment routinely for transfusion recipi-
ents in endemic areas reflects WHO guidelines [6] and the advice
in several published papers [13–16]. In contrast, other papers
recommend restricting malaria treatment to selected ‘at risk’
transfusion recipients such as neonates [17–19]. However,
evidence that transfusion-transmitted malaria is a significant
clinical problem in endemic areas is almost non-existent. One
study has documented malaria parasitaemia occurring in recipi-
ents of malaria-positive transfusions in Sudan [20], but we have
recently observed that the majority of transfusion recipients in
Ghana who developed parasitaemia post transfusion did not
acquire it from the blood transfusion as parasite genotyping
indicated that malaria transmission only occurred in 2% of those
who received a malaria-positive blood transfusion (unpublished
data).
Table 3. A comparison of anti-malarial use among children
with and without clinical features of malaria.
Malaria
(N=41)
Non-malaria
(N=18)
Median age (IQR) years 2.0 (1.0–4.0) 5.0 (1.8–9.3)
Children ,5 yrs (%) 34 (82.9) 10 (55.5)
Anti-malarial use (%) 41 (61.0) 10 (55.5)
Type of anti-malarial given (%)
Quinine* 25 (61.0) 1 (10)
Artemether-Lumefantrine 1 (2.4) 2 (20)
Artesunate-Amodiaquine 15 (36.0) 7 (70)
*recommended for severe malaria.
doi:10.1371/journal.pone.0034201.t003
Figure 1. Recommendations concerning transfusion-transmitted malaria in malaria endemic countries in Africa. A summary of
recommendations from the current situation of transfusion-transmitted malaria in malaria endemic countries in Africa.
doi:10.1371/journal.pone.0034201.g001
Transfusion Malaria Policies and Practice in Ghana
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34201
There have been no studies from endemic areas comparing
presumptive versus targeted malaria treatment for transfusion
recipients and there is very scanty evidence underpinning
recommendations for presumptive malaria treatment of transfu-
sion recipients. In contrast, current malaria treatment guidelines
recommending that treatment should only be given to those with
proven infections [9] are well-supported by evidence and are
designed to slow down the emergence of P. falciparum resistance
to artemisinin [21,22]. There has been a rise in the proportion of
febrile patients with laboratory confirmation of malaria from 5%
in 2000 to 35% in 2009 [1]. Although patients with negative
malaria tests are still being treated for malaria [23] a Ugandan
study has demonstrated that it is possible to improve the rates of
diagnostic malaria testing and to restrict malaria treatment to
those with positive results [24].
Our study found that the restrictive malaria treatment policy
is not implemented in the context of blood transfusions in a
malaria endemic area. International guidelines do allow for
presumptive treatment of malaria if laboratory confirmation is
not available [9] but any facility that is able to offer blood
transfusion will almost certainly have a laboratory capable of
providing a definitive diagnosis of malaria. The practice of
treating every fever presumptively for malaria is entrenched
[25] and our study demonstrated that in practice, and
particularly in paediatric practice, clinicians choose presumptive
treatment for transfusion recipients rather than laboratory
confirmation of malaria diagnosis prior to initiation of
treatment. Implementation of the WHO recommendations to
screen donated blood for malaria is hampered by a lack of
suitable screening methods [4] which may partly explain the
emphasis on presumptive treatment as an alternative strategy.
Our study shows widespread prescribing of anti-malarials with
transfusion especially in paediatric practice. These prescriptions
are based on assumptions about the need for anti-malarials as
prophylaxis against transfusion transmitted malaria or as
treatment for malaria as a cause of anaemia. Quinine is the
recommended treatment for severe malaria and was prescribed
for the majority of children with clinically-diagnosed malaria
(61%). Severe malaria requiring urgent treatment is a justifica-
tion for initiating treatment for malaria without waiting for
laboratory confirmation.
The mean duration of transfusion in children was longer than in
adults and diuretics were prescribed with the blood transfusion for
88% of children. These practices do not appear to be consistent
with any policies or guidelines but are based on assumptions that
the symptoms of severe malarial anaemia, particularly respiratory
distress, result from biventricular failure [26] and that these
children are not hypovolaemic [27]. Recent evidence has shown
that children with severe febrile illness and impaired perfusion do
not benefit from fluid resuscitation [28]. Clinical guidelines [6]
indicate that diuretics should only be used in transfusion recipients
likely to develop or who develop cardiac failure. 88% of children
in our study were given furosemide with their blood transfusion
and in almost all cases there was no indication of why it was given.
The use of concomitant antibiotic in transfusion recipients
ranged from 61–96% across the three departments and is likely to
represent treatment for underlying conditions. In clinical practice
in Africa it can be difficult to differentiate between severe malaria
and sepsis, and both conditions may co-exist [29]. Among anaemic
children in Malawi who were transfused for severe anaemia, 64%
of them had malaria parasitaemia. In this study a pathogen was
isolated from blood cultures in 24.7% of patients with post
transfusion fever [30]. Recent data from Kenya [31] has shown an
8.8% bacterial contamination rate of paediatric whole blood, and
may suggest that sepsis plays an important role in post transfusion
fever. Ideally blood cultures should be taken before empirical
antibiotics are started [32] but it is common for antibiotics and
anti-malarials to be prescribed simultaneously [9,33] and there is
evidence that this approach may reduce mortality in severe
malaria [34]. More studies are needed to establish the effects of
bacterial contamination on transfusion recipients and the role, if
any, of concomitant antibiotic use with transfusion.
These results of this study have enabled us to make several
recommendations concerning transfusion-transmitted malaria
(Figure 1). We have shown that where international malaria and
transfusion policies are in conflict, such as restricting anti-malarials
to proven infections versus presumptive treatment of transfusion
recipients, clinicians choose to adhere to transfusion policies rather
Table 4. Summary of policies and practices concerning transfusion transmitted malaria.
WHO recommendations Policies in Ghana Practice in KATH Research knowledge needed about..
Donated blood should be tested for
malaria [5]
All units to be tested for HIV I & II,
Hepatitis B and C and syphilis and
any other transfusion transmissible
disease [35]
No malaria screening of donated blood Screening methods for malaria that are
practical and sensitive enough for use by
transfusion services
In endemic areas, there is a high risk of
transmitting malaria by transfusion. All
transfusion recipients should receive
routine treatment for malaria [6]
No policy on routine treatment
for malaria
37% of transfusion recipients received
anti-malarials with their transfusion or
within 24 hours post-transfusion
Cost-effectiveness of malaria screening in
different transmission zones
Anti-malarials should only be prescribed
for proven malaria infections [9]
Confirm cases of malaria before initiating
treatment (treatment can be started in
severe cases but a confirmation from the
laboratory is needed) [12]
3% (2/66) had a laboratory confirmation
of malaria before treatment
Rates of malaria transmission by
transfusion with genotyping to confirm
that malaria was acquired through
transfusion
Effectiveness of presumptive malaria
treatment of transfusion recipients
compared to treatment restricted to
proven infections
In patients at risk of circulatory overload,
red cells are preferable to whole blood.
Treat volume overload and cardiac
failure with diuretics [6]
Diuretics should only be given in
recipients with heart failure. For
patients with heart failure lower
the rate of transfusion [36]
88% of children were given diuretics Effective approaches for ensuring that
transfusion guidelines are evidence-
based, regularly reviewed and
implemented
doi:10.1371/journal.pone.0034201.t004
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than malaria policies (Table 4) even though malaria policies have a
much stronger evidence base than transfusion policies. Neverthe-
less, there is still widespread inappropriate use of anti-malarials in
the context of blood transfusion in Africa. There is an urgent need
for harmonised policy-making by malaria and blood transfusion
programmes so that clinicians, and particularly paediatricians,
receive clear messages about how to reduce malaria transmission
through blood transfusions. This harmonisation needs to be
preceded by research to generate better knowledge about the
prevalence and clinical impact of transfusion transmitted malaria,
and about the cost-effectiveness of various blood donor screening
strategies taking account of the need to avoid exacerbating blood
shortages by unnecessarily excluding donors. Our study has
demonstrated that until these critical gaps in the evidence about
transfusion-transmitted malaria are addressed and the relevant
policies are harmonised, these mixed messages will continue to be
translated into inconsistent management of patients receiving
blood transfusions in malaria-endemic areas.
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